M

MaxCyte Inc
NASDAQ:MXCT

Watchlist Manager
MaxCyte Inc
NASDAQ:MXCT
Watchlist
Price: 4.11 USD 1.23% Market Closed
Market Cap: 433.5m USD
Have any thoughts about
MaxCyte Inc?
Write Note

Net Margin
MaxCyte Inc

-78.4%
Current
-71%
Average
0.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-78.4%
=
Net Income
-35.7m
/
Revenue
45.6m

Net Margin Across Competitors

Country US
Market Cap 432.8m USD
Net Margin
-78%
Country US
Market Cap 1.2T USD
Net Margin
9%
Country US
Market Cap 202.3B USD
Net Margin
14%
Country US
Market Cap 166.6B USD
Net Margin
18%
Country KR
Market Cap 66.8T KRW
Net Margin
24%
Country CH
Market Cap 38.4B CHF
Net Margin
9%
Country US
Market Cap 38.8B USD
Net Margin
20%
Country US
Market Cap 36.3B USD
Net Margin
9%
Country US
Market Cap 27B USD
Net Margin
21%
Country US
Market Cap 24.1B USD
Net Margin
17%
Country CN
Market Cap 162.8B CNY
Net Margin
21%
No Stocks Found

MaxCyte Inc
Glance View

Market Cap
432.8m USD
Industry
Life Sciences Tools & Services

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

MXCT Intrinsic Value
3.37 USD
Overvaluation 18%
Intrinsic Value
Price
M

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-78.4%
=
Net Income
-35.7m
/
Revenue
45.6m
What is the Net Margin of MaxCyte Inc?

Based on MaxCyte Inc's most recent financial statements, the company has Net Margin of -78.4%.